TalkMed Group Limited (5G3.SI)
- Previous Close
0.4150 - Open
0.4100 - Bid 0.4050 x --
- Ask 0.4100 x --
- Day's Range
0.4100 - 0.4150 - 52 Week Range
0.3550 - 0.4550 - Volume
4,200 - Avg. Volume
19,346 - Market Cap (intraday)
550.564M - Beta (5Y Monthly) 0.20
- PE Ratio (TTM)
20.75 - EPS (TTM)
0.0200 - Earnings Date Feb 20, 2024
- Forward Dividend & Yield 0.03 (6.27%)
- Ex-Dividend Date Apr 30, 2024
- 1y Target Est
--
TalkMed Group Limited, an investment holding company, provides medical oncology, stem cell transplants, palliative care, and other related services in Singapore, China, Hong Kong, Vietnam, India, New Zealand, Australia, and the United States. It operates through two segments: Oncology Services; and Cellular and Gene Therapy Related Products and Services. The company offers medical oncology services in the areas of breast, colon, lung, liver, biliary and pancreatic, gastro-intestinal, head and neck, genitourinary and gynaecological, and haematology malignancies and brain cancers, as well as lymphoma and leukaemia. It also provides palliative care services comprising cancer pain management, discharge and home care planning, advance care planning, and end-of-life care planning; and ancillary health services, such as CANSCREEN, a screening program that provides screening for individuals at a risk of getting cancer. In addition, the company offers goods and services related to cellular and gene therapy; specialist doctors and clinical staff services; and healthcare management services. Further, the company develops novel processing platforms for cell and gene therapy and carrying out research in genetic modification of immune cells; and novel platform viral vector technologies that strive to advance genetic modification of cellular therapy through basic vector system design. TalkMed Group Limited was founded in 1997 and is based in Singapore. TalkMed Group Limited operates as a subsidiary of Citibank Nominees Singapore Pte Ltd.
www.talkmed.com.sg232
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 5G3.SI
Performance Overview: 5G3.SI
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 5G3.SI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 5G3.SI
Valuation Measures
Market Cap
550.57M
Enterprise Value
469.85M
Trailing P/E
17.15
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.60
Price/Book (mrq)
6.11
Enterprise Value/Revenue
5.61
Enterprise Value/EBITDA
11.47
Financial Highlights
Profitability and Income Statement
Profit Margin
38.40%
Return on Assets (ttm)
21.58%
Return on Equity (ttm)
34.82%
Revenue (ttm)
83.79M
Net Income Avi to Common (ttm)
32.18M
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
89.9M
Total Debt/Equity (mrq)
10.92%
Levered Free Cash Flow (ttm)
32.12M
Company Insights: 5G3.SI
5G3.SI does not have Company Insights